rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IMMP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial
      Nov 11BenzingaIMMP
      Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies

      SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number 12,788,796) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent and Trademark Office (USPTO). With this latest grant, Immutep now holds five United States patents within this patent family. The portfolio has expanded p

      Nov 10Yahoo FinanceIMMP
      IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
      Nov 8Yahoo FinanceIMMP
      Immutep Quarterly Activities Report Q1 FY27
      Oct 29Yahoo FinanceIMMP
      Immutep receives €1.36 million French R&D tax payment
      Oct 28Investing.comIMMP
      Immutep Receives A$2.16 million French R&D Tax Incentive

      SYDNEY, AUSTRALIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) research tax incentive program, for eligible R&D activities conducted in calendar year 2025. The CIR is a French Government inc

      Oct 28Yahoo FinanceIMMP
      Immutep Sets Out Governance and Market Footing in 2026 Annual Report

      Detailed price information for Immutep Ltd Ord (PRRUF) from The Globe and Mail including charting and trades.

      Oct 28The Globe and MailIMMP
      Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
      Oct 23Yahoo FinanceIMMP
      Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
      Oct 19Yahoo FinanceIMMP
      Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
      Oct 14Yahoo FinanceIMMP
      Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
      Oct 13Yahoo FinanceIMMP
      Immutep Restores Nasdaq Bid Price Compliance with ADS Ratio Change

      Detailed price information for Immutep Ltd Ord (PRRUF) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailIMMP
      Immutep Announces Board Resignation and Search for New Non-Executive Director

      Detailed price information for Immutep Ltd Ord (PRRUF) from The Globe and Mail including charting and trades.

      Oct 5The Globe and MailIMMP
      Immutep Details Equity Interests of Departing Director Pete Meyers

      Detailed price information for Immutep Ltd Ord (PRRUF) from The Globe and Mail including charting and trades.

      Oct 5The Globe and MailIMMP
      Immutep receives A$856,669 R&D tax rebate from Australia
      Sep 30Investing.comIMMP
      Immutep Receives ~A$0.86 Million R&D Tax Incentive

      SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate was provided in respect of expenditure incurred on eligible R&D activities conducted in the 2025 fiscal year. This follows approval from AusIndustry of Immu

      Sep 30Yahoo FinanceIMMP
      Immutep (IMMP) Stock Analysis Report | Financials & Insights
      Sep 27BenzingaIMMP
      Immutep Resets ADS Ratio to Bolster Nasdaq Listing Compliance

      Detailed price information for Immutep Ltd ADR (IMMP-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailIMMP
      Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
      Sep 11Yahoo FinanceIMMP
      Immutep Refocuses Efti Development After Manufacturing Probe

      Detailed price information for Immutep Ltd Ord (PRRUF) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailIMMP

      This is the newest page. Registered accounts read further back.